# Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

> **NCT01547598** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 135 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** travoprost ophthalmic solution 0.004%
- **DRUG:** travoprost 0.004% / timolol 0.5% combination ophthalmic solution
- **DRUG:** Bimatoprost ophthalmic solution 0.01%

## Key facts

- **NCT ID:** NCT01547598
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2014-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01547598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01547598, "Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01547598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*